Inventiva (NASDAQ:IVA) Shares Gap Down - Here's What Happened

Key Points

• Inventiva S.A. (NASDAQ:IVA) experienced a gap down in share price, opening at $5.44 after closing the previous day at $5.77, and trading at $5.54.
• Equities research analysts have set new price targets for Inventiva, with Guggenheim raising their target from $9.00 to $13.00, and Piper Sandler setting a target of $26.00.
• Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 54.5%, owning 16,558 shares after a recent purchase.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $5.77, but opened at $5.44. Inventiva shares last traded at $5.54, with a volume of 5,620 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Piper Sandler assumed coverage on shares of Inventiva in a report on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 target price for the company. HC Wainwright assumed coverage on shares of Inventiva in a report on Wednesday, September 3rd. They issued a "buy" rating and a $20.00 target price for the company. Finally, Guggenheim increased their target price on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Inventiva currently has a consensus rating of "Moderate Buy" and an average price target of $14.83.

Inventiva Stock Performance

The stock's 50 day moving average price is $4.15 and its two-hundred day moving average price is $3.56.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.